Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a ...

Sept 1 (Reuters) - U.S. health regulators on Thursday approved a label update to Novartis AG's osteoporosis drug Reclast to warn about the risk of kidney failure associated with the use of the drug.